CSIMarket
 


Fibrogen Inc   (NASDAQ: FGEN)
Other Ticker:  
 

Fibrogen Inc 's Quick Ratio

FGEN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth

 


Current Liabilities decreased faster than Fibrogen Inc 's Cash & cash equivalent, this led to improvement in Fibrogen Inc 's Quick Ratio to 0.46, Quick Ratio remained below Fibrogen Inc average.

Within Major Pharmaceutical Preparations industry 395 other companies have achieved higher Quick Ratio than Fibrogen Inc in first quarter 2025. While Quick Ratio total ranking has improved so far during the Q1 2025 to 2210, from total ranking in the fourth quarter 2024 at 2699.

Explain Quick Ratio?
How much Cash & cash equivalents FGEN´s has?
What are FGEN´s Current Liabilities?


FGEN Quick Ratio (Mar 31 2025)
Q1
(Dec 31 2024)
Q4
(Sep 30 2024)
Q3
(Jun 30 2024)
Q2
(Mar 31 2024)
Q1
Y / Y Current Liabilities Change -62.7 % -38.76 % -9.02 % -23.44 % -22.77 %
Y / Y Cash & cash equivalent Change -81.08 % -78.57 % -47.88 % -58.09 % -50.11 %
Quick Ratio MRQ 0.46 0.38 0.69 0.95 0.9
FGEN's Total Ranking # 2210 # 2699 # 2180 # 1850 # 1927
Seq. Current Liabilities Change -44.95 % -30.03 % 28.23 % -24.47 % -9.62 %
Seq. Cash & cash equivalent Change -33.42 % -61.47 % -6.9 % -20.77 % -24.61 %



Quick Ratio first quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 396
Healthcare Sector # 719
Overall Market # 2210


Quick Ratio Statistics
High Average Low
10.66 4.02 0.38
(Sep 30 2017)   (Dec 31 2024)




Financial Statements
Fibrogen Inc 's Current Liabilities $ 73 Millions Visit FGEN's Balance sheet
Fibrogen Inc 's Cash & cash equivalent $ 34 Millions Visit FGEN's Balance sheet
Source of FGEN's Sales Visit FGEN's Sales by Geography


Cumulative Fibrogen Inc 's Quick Ratio

FGEN's Quick Ratio for the trailling 12 Months

FGEN Quick Ratio

(Mar 31 2025)
12 Months
(Dec 31 2024)
12 Months
(Sep 30 2024)
12 Months
(Jun 30 2024)
12 Months
(Mar 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth -33.27 % -23.6 % -19.13 % -20.73 % -19.87 %
Y / Y Cash & cash equivalent TTM Growth -64.43 % -57.59 % -49.82 % -47.1 % -38.43 %
Quick Ratio TTM 0.65 0.75 0.91 1.04 1.22
Total Ranking TTM # 2423 # 2506 # 3390 # 3359 # 3347
Seq. Current Liabilities TTM Growth -18.43 % -11.2 % -2.44 % -5.56 % -6.62 %
Seq. Cash & cash equivalent TTM Growth -28.81 % -27.03 % -14.94 % -19.5 % -15.13 %


On the trailing twelve months basis In spite of the year on year decrease in FGEN's Current Liabilities to $73.39 millions, cumulative Quick Ratio to 0.65 below the FGEN average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 350 other companies have achieved higher Quick Ratio than Fibrogen Inc . While Quick Ratio overall ranking has improved so far to 2423, from total ranking during the twelve months ending fourth quarter 2024 at 2506.

Explain Quick Ratio?
How much Cash & cash equivalents FGEN´s has?
What are FGEN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 351
Healthcare Sector # 692
Within the Market # 2423


trailing twelve months Quick Ratio Statistics
High Average Low
8.89 4.23 0.65
(Jun 30 2018)   (Mar 31 2025)




Companies with similar Quick Ratio in the quarter ending Mar 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2025 MRQ Cash & cash equivalentMar 31 2025 MRQ Current Liabilities
Akebia Therapeutics Inc   1.24 $ 113.374  Millions$ 91.227  Millions
Rein Therapeutics Inc   1.24 $ 7.428  Millions$ 5.977  Millions
Fortress Biotech Inc   1.24 $ 91.339  Millions$ 73.674  Millions
Axsome Therapeutics Inc   1.23 $ 300.910  Millions$ 243.914  Millions
Nature s Sunshine Products inc   1.22 $ 86.486  Millions$ 70.741  Millions
Neonc Technologies Holdings Inc   1.22 $ 5.439  Millions$ 4.470  Millions
Bioxcel Therapeutics Inc   1.21 $ 31.013  Millions$ 25.546  Millions
Therapeuticsmd Inc  1.21 $ 5.745  Millions$ 4.741  Millions
Aeon Biopharma inc   1.21 $ 10.446  Millions$ 8.640  Millions
Evoke Pharma Inc   1.21 $ 12.624  Millions$ 10.452  Millions
Evolus Inc   1.21 $ 67.894  Millions$ 56.233  Millions
Amphastar Pharmaceuticals Inc   1.20 $ 239.083  Millions$ 199.052  Millions
Zomedica Corp   1.19 $ 8.837  Millions$ 7.405  Millions
Unicycive Therapeutics Inc  1.19 $ 19.769  Millions$ 16.676  Millions
Gri Bio Inc   1.18 $ 3.281  Millions$ 2.779  Millions
Zymeworks Inc   1.17 $ 76.204  Millions$ 65.103  Millions
Rigel Pharmaceuticals Inc  1.16 $ 77.099  Millions$ 66.629  Millions
Salarius Pharmaceuticals inc   1.14 $ 1.798  Millions$ 1.583  Millions
Moleculin Biotech Inc   1.12 $ 7.716  Millions$ 6.896  Millions
Durect Corp  1.08 $ 8.260  Millions$ 7.673  Millions
Puma Biotechnology Inc   1.08 $ 93.167  Millions$ 86.663  Millions
Fibrobiologics Inc   1.06 $ 8.667  Millions$ 8.211  Millions
Supernus Pharmaceuticals inc   1.04 $ 115.848  Millions$ 111.639  Millions
Johnson and Johnson  1.02 $ 38,781.000  Millions$ 38,123.000  Millions
Rockwell Medical inc   1.02 $ 11.391  Millions$ 11.205  Millions
Verrica Pharmaceuticals Inc   1.01 $ 29.595  Millions$ 29.396  Millions
180 Life Sciences Corp  0.94 $ 3.725  Millions$ 3.942  Millions
Sarepta Therapeutics Inc   0.93 $ 522.762  Millions$ 560.729  Millions
Royalty Pharma Plc  0.93 $ 1,099.820  Millions$ 1,182.852  Millions
Ibio inc   0.92 $ 4.985  Millions$ 5.397  Millions

Date modified: 2025-05-15T04:07:47+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com